Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessEfficacy and safety of TDF/FTC-containing, first-line HAART in clinical practice: 3-year data from the German outpatient cohort
-
Article
Open Access0314. Efficacy and safety of peginterferon alfa-2a + RBV in cHCV/HIV- vs cHCV-infected patients: interim analysis of a multicenter German cohort
-
Article
Open AccessOnce-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naïve patients
-
Article
Open AccessThe Rainbow Cohort: saquinavir/r is effective and well tolerated in antiretroviral therapy (ART)-naïve patients – 48-week results from Germany
-
Article
Open AccessAntiretroviral tolerability and efficacy after switch to saquinavir in PI-experienced patients: 48-week analysis of the German Rainbow Cohort
-
Article
Open AccessLipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors
-
Article
Open AccessEfficacy and safety of TDF/FTC-containing first-line HAART in clinical practice – 2-year data from the German Outpatient Cohort